Ali Mijoba

Prof. Ali Mijoba

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2023 in Molecules
Verified
Journal Article
Open access
PDF file
AMAli Mijoba
Ali Mijoba
EFEsteban Fernandez-Moreira
Esteban Fernandez-Moreira
NGNereida Parra Gimenez
Nereida Parra Gimenez
SESandra Espinosa
Sandra Espinosa
ZMZuleyma Blanco Marquez
Zuleyma Blanco Marquez
Jaime CharrisJaime Charris
Jaime Charris
A series of benzocycloalkanone derivatives have been prepared and evaluated as antimalarial and antitrypanosomal agents. The compounds were obtained by direct coupling of preformed 4-substituted benzaldehyde and indanone or tetralone substitutes through aldol condensation of Claisen-Schmidt using sodium hydroxide as a catalyst in ethanol at room temperature. Although designed to inhibit the formation of β-hematin in vitro, only three compounds, 10, 11, and 12, showed activities greater than 50% (75.16%, 63.02%, and 56.17%, respectively). The results of the in vivo antimalarial evaluation show that 10, 11, and 12 reduced parasitemia marginally, and an insignificant increase in the days of survival of the mice was observed. As trypanocidals, all compounds showed marginal activity as inhibitors of the proliferation of T. cruzi epimastigotes, except compound 33, with an activity of 51.08 ± 3.4% compared to the activity shown by the reference compound benznidazole 59.99 ± 2.9%. The compounds appear to have little cytotoxic effect against VERO cells in vitro; this new class of Michael acceptor agents clearly warrants further investigation.

30 August 2024 in Molecules
Verified
Journal Article
Open access
PDF file
AMAli Mijoba
Ali Mijoba
NGNereida Parra Gimenez
Nereida Parra Gimenez
EFEsteban Fernandez-Moreira
Esteban Fernandez-Moreira
HPHegira Hegira Ramírez Padilla
Hegira Hegira Ramírez Padilla
XMXenón Serrano Martín
Xenón Serrano Martín
Jaime CharrisJaime Charris
Jaime Charris
The aim of this work was to obtain and evaluate, as antiprotozoals, new derivatives of benzoate imidazo-1,3,4-thiadiazole 18–23 based on the concepts of molecular repositioning and hybridization. In the design of these compounds, two important pharmacophoric subunits of the fexnidazole prototype were used: metronidazole was used as a repositioning molecule, p-aminobenzoic acid was incorporated as a bridge group, and 1,3,4-thiadiazole group was incorporated as a second pharmacophore, which at position 5 has an aromatic group with different substituents incorporated. The final six compounds were obtained through a five-step linear route with moderate to good yields. The biological results demonstrated the potential of this new class of compounds, since three of them 19–21 showed inhibitory activity on proliferation, in the order of 50%, in the in vitro assay against epimastigotes of T. cruzi (Strain Y sensitive to nifurtimox and benznidazole) and promastigotes of L. donovani, at a single concentration of 50 μM.

31 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
ZMZuleyma Blanco Marquez
Zuleyma Blanco Marquez
EFEsteban Fernandez-Moreira
Esteban Fernandez-Moreira
MMMichael Rodney Mijares
Michael Rodney Mijares
CCCarmen Celis
Carmen Celis
Gricelis Patricia MartinezGricelis Patricia Martinez
Gricelis Patricia Martinez
Jaime CharrisJaime Charris
Jaime Charris
The coexistence of leishmaniasis, Chagas disease, and neoplasia in endemic areas has been extensively documented. The use of common drugs in the treatment of these pathologies invites us to search for new molecules with these characteristics. In this research, we report 16 synthetic chalcone derivatives that were investigated for leishmanicidal and trypanocidal activities as well as for antiproliferative potential on eight human cancers and two nontumor cell lines. The final compounds 8–23 were obtained using the classical base-catalyzed Claisen–Schmidt condensation. The most potent compounds as parasiticidal were found to be 22 and 23, while compounds 18 and 22 showed the best antiproliferative activity and therapeutic index against CCRF-CEM, K562, A549, and U2OS cancer cell lines and non-toxic VERO, BMDM, MRC-5, and BJ cells. In the case of K562 and the corresponding drug-resistant K562-TAX cell lines, the antiproliferative activity has shown a more significant difference for compound 19 having 10.3 times higher activity against the K562-TAX than K562 cell line. Flow cytometry analysis using K562 and A549 cell lines cultured with compounds 18 and 22 confirmed the induction of apoptosis in treated cells after 24 h. Based on the structural analysis, these chalcones represent new compounds potentially useful for Leishmania, Trypanosoma cruzi, and some cancer treatments.

25 June 2024 in Revista de La Facultad de Farmacia, Universidad Central de Venezuela
Verified
Journal Article
Open access
PDF file
AMAli Mijoba
Ali Mijoba
FOFacultad de Farmacia Laboratorio de Síntesis Orgánica
Facultad de Farmacia Laboratorio de Síntesis Orgánica
ZBZuleyma Blanco
Zuleyma Blanco
NPNereida Parra
Nereida Parra
FGFrancis Gómez
Francis Gómez
JCJaime Charris
Jaime Charris
La síntesis y comportamiento tripanocida y leishmanicida de una serie de 2-fenilbenzotiazoles es reportada. Fue necesario optimizar el rendimiento del intermediario clave 3, para lo cual se modularon algunas variables como: tiempo de reacción, temperatura de la reacción y la base utilizada, el mejor resultado se alcanzó cuando fue usada solución hidroalcohólica de KOH al 35%. La actividad in vitro contra epimastigotes de T. cruzi, un parásito responsable de la enfermedad de Chagas y promastigotes de L. braziliensis, parásito responsable de la leishmaniasis cutánea ha sido prometedora, especialmente los resultados anti-T. cruzi encontrados para los compuestos 6 y 11, con valores de inhibición de la proliferación de 52,76 ± 2,28 y 51,80 ± 3,11%, respectivamente, y como leishmanicida los compuestos 5 y 6 resultaron con valores de 48,94 ± 0,15 y 45,56 ± 2,12%, respectivamente, comparado con las drogas de uso clínico benznidazol y miltefosina 52,88 ± 1,77 y 48,12 ± 1,15%, respectivamente. Estudios adicionales están aún en proceso, necesarios para determinar su comportamiento in vivo y el mecanismo de acción.